HR-2592-119
Referred to the House Committee on Transportation and Infrastructure.
Sponsored by Sean Casten (D-IL)
What it does
The Aviation Medication Transparency Act of 2025 would establish requirements related to the disclosure of medications used by commercial airline pilots, likely to the FAA or relevant aviation authorities. Because only the bill's title is available — the full text was not provided — the precise mechanical details (which medications, which pilots, which disclosure recipients, and what consequences follow) cannot be determined from the available information.
Who benefits
The traveling public, who would have greater assurance that pilot fitness-for-duty standards account for medication use. Aviation safety regulators (FAA) who would gain more complete health information about pilots. Airlines' safety and compliance departments. Passengers with heightened safety concerns, including frequent flyers. Potentially, pilots who currently self-disclose and compete against those who do not.
Who is hurt
Pilots who use prescription medications and may face additional scrutiny, reporting burdens, or disqualification from flying. Pilots with managed chronic conditions (e.g., depression, hypertension) who may avoid seeking treatment to preserve their medical certificates. Physicians treating pilots, who may face new reporting obligations. Smaller regional airlines with fewer compliance resources. Pilot unions and associations that may view expanded disclosure as an intrusion on medical privacy.
Supporters argue
Supporters argue that aviation safety depends on complete and accurate health information, and that gaps in medication disclosure have been implicated in past incidents — including the 2015 Germanwings crash, where the co-pilot had undisclosed psychiatric treatment. They contend that transparency requirements would close known loopholes in the FAA's medical certification process, where pilots may obtain medications through providers outside the system used for FAA medical exams, making the skies safer for the roughly 900 million passengers who fly in the U.S. annually.
Opponents argue
Opponents argue that overly broad medication disclosure requirements could deter pilots from seeking treatment for manageable conditions like depression or anxiety, paradoxically creating greater safety risks than the ones the bill aims to prevent. They contend that existing FAA medical certification standards already require disclosure of medical conditions and that adding medication-specific mandates may violate pilots' medical privacy rights under HIPAA and the Americans with Disabilities Act without a demonstrated safety benefit proportionate to the intrusion.